



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Clindamycin (Standard)

| | |
|---------------------------|---|
| Cat. No.: | HY-B1455R |
| CAS No.: | 18323-44-9 |
| Molecular Formula: | C ₁₈ H ₃₃ ClN ₂ O ₅ S |
| Molecular Weight: | 424.98 |
| Target: | Bacterial; Parasite; Antibiotic |
| Pathway: | Anti-infection |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|--|
| Description | Clindamycin (Standard) is the analytical standard of Clindamycin. This product is intended for research and analytical applications. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in <i>Staphylococcus aureus</i> at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria ^{[1][2]} . |
| IC₅₀ & Target | MIC Target:Clindamycin ^[4] MIC: 200 µg/mL (<i>E. coli</i>) ^[4] |

REFERENCES

- [1]. Hodille E, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant *Staphylococcus aureus* strains. *Ann Clin Microbiol Antimicrob.* 2018 Oct 20;17(1):38.
- [2]. Kreamsner PG. Clindamycin in malaria treatment. *J Antimicrob Chemother.* 1990 Jan;25(1):9-14.
- [3]. Kishi K, et al. Clindamycin suppresses endotoxin released by ceftazidime-treated *Escherichia coli* O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. *Antimicrob Agents Chemother.* 1999 Mar;43(3):616-22.
- [4]. Veringa EM, et al. Clindamycin at subinhibitory concentrations enhances antibody- and complement-dependent phagocytosis by human polymorphonuclear leukocytes of *Staphylococcus aureus*. *Chemotherapy.* 1987;33(4):243-9.
- [5]. Naal FD, et al. The effects of clindamycin on human osteoblasts in vitro. *Arch Orthop Trauma Surg.* 2008 Mar;128(3):317-23.
- [6]. Faggion PI, et al. Is the penetration of clindamycin into the masseter muscle really enough to treat odontogenic infections? *Clin Oral Investig.* 2021 May;25(5):3257-3266.
- [7]. Yang SH, Lee MG. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability. *Int J Pharm.* 2007 Mar 6;332(1-2):17-23.
- [8]. Hirata N, et al. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. *Antimicrob Agents Chemother.* 2001 Sep;45(9):2638-42.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA